Abstract Deficient retro-aortic rim is of concern as a risk factor for aortic erosion after device closure of atrial septal defects (ASD). However, its prevalence and contribution to technical failure and adverse outcomes have not been delineated. A single-center retrospective cohort study of children and adults undergoing cardiac catheterization for device occlusion of ASD from 1 January 1999 to 1 April 2012 was performed. Risk factors for technical failure and early adverse outcome were assessed using multivariate logistic regression. During the study period, 445 consecutive subjects with a median age of 5.9 years (range, 0.8-80 years) underwent catheterization. Of the subjects with reviewable echocardiograms, 60 % had deficient retroaortic rim. No attempt at device closure was made for 3.6 % of the subjects. Of the remaining 429 subjects, 96 % underwent successful device occlusion. Major early adverse events occurred in 1.2 % (95 % confidence interval 0.4-2.7 %) of the cases, all of them either device embolization or malposition. Deficient retro-aortic rim was not a risk factor for composite outcome of technical failure or early major adverse event. No deaths, late reinterventions, or erosion events occurred during 2,395 total person-years (median, 5.8 years) of follow-up evaluation. Deficient retroaortic rim was associated with increased risk of device impingement on the aorta, but no association was seen between device impingement or deficient retro-aortic rim and the development of new/progressive aortic insufficiency. Deficient retro-aortic rim is highly prevalent but did not increase the risk of adverse outcomes. Its contribution to the risk of aortic erosion could not be addressed by this study.
implicated deficient retro-aortic rim as a potential risk factor [3, 4] , leading to changes in recommendations for device use [5, 15, 20] . However, the prevalence of deficient retro-aortic rim in children and adults who have undergone device closure has not been well defined, limiting ability to determine the degree to which it represents a true risk factor for erosion.
We performed a single-institution retrospective cohort study of children and adults undergoing catheterization for possible device occlusion of ASD to assess the prevalence of deficient retro-aortic rim and to determine whether it affects the risk of either technical failure or treatmentassociated adverse events.
Methods

Study Population
The study protocol was approved by the institutional review board of The Children's Hospital of Philadelphia, and waiver of consent was granted. We conducted a retrospective cohort study based on review of medical records and imaging data from subjects treated at The Children's Hospital of Philadelphia (Philadelphia, Pennsylvania). Subjects were identified through our center's cardiac catheterization laboratory and cardiac surgical databases. Children and adults across all ages were included if they underwent cardiac catheterization for possible device closure of ASD between 1 January 1999 and 1 April 2012. Subjects referred for operative closure without cardiac catheterization were not included in the study. No additional exclusion criteria were applied.
Study Procedures
Medical records were reviewed including precatheterization assessments, inpatient admissions and emergency room visits, clinic letters, catheterization reports, angiograms, and echocardiograms performed during the study period. Subject demographics (age, sex, and race), growth parameters (height, weight, body surface area, and body mass index), and clinical history (cardiac and noncardiac medical and operative history) were extracted. Data from cardiac catheterizations including oximetry, hemodynamics, exposure to radiation, contrast dose, and procedural adverse events were extracted from catheterization reports and records from hospitalization.
During the study period, the approach to device closure was consistent with device placement guided by fluoroscopy and either transesophageal or intracardiac echocardiography. For subjects with deficient retro-aortic rim, operators did not systematically vary their device deployment technique using previous variations [1, 2] . Specific variations in deployment technique were not recorded as part of the data collected for this study. Defect size was measured by echocardiography with balloon sizing using the stop-flow technique.
Echocardiograms available on the digital imaging system were reviewed by one member of the study staff (M.L.O.). The echocardiograms reviewed included the first transthoracic echocardiogram (TTE) before cardiac catheterization, the echocardiogram performed during catheterization, the first postprocedural echocardiogram, and the most recent echocardiogram within the study period. All measurements were performed with the operator blinded to original clinical reports, prior and subsequent echocardiograms, and clinical outcomes.
On the preprocedural echocardiogram, septal length and defect size in orthogonal views (subcostal frontal and sagittal), tissue rims (right upper pulmonary vein, superior vena cava, inferior vena cava, mitral valve, and aorta), presence of valvar insufficiency, and presence of rightsided atrial and ventricular enlargement were measured. On the procedural echocardiograms, septal length, retro-aortic rim, and maximal defect size were measured. Deficient retro-aortic rim was defined as a retro-aortic rim measuring 5 mm or less in any view on the echocardiogram, as described previously [3, 4, 21] .
Defect size during balloon inflation using the stop-flow technique (used in all cases) also was measured, with device sizing based on this measurement. The presence of residual shunt; pericardial effusion; impingement on the mitral and tricuspid valve, pulmonary veins, inferior vena cava, or superior vena cava; impingement on or contact with the aorta; or presence of aortic insufficiency, device thrombus, device malposition, arrhythmia, or device fracture was extracted from the first and most recent postprocedural echocardiograms.
The presence of impingement on the aorta was recorded. The manner in which the implanted device impinged on the aortic valve also was recorded, with impingement divided between ''splaying'' of the device around the aorta and impingement of the device on the aorta perpendicular to the aortic wall (''poking'') with or without deformation of the valve.
To assess interrater reliability, 40 randomly selected preprocedural studies were remeasured by another member of the study staff (D.J.G.). The 40 studies represented a 20 % sample of the 205 digitally available echocardiograms from subjects with single ostium secundum ASD. Intraclass correlation coefficients for continuous variables were calculated. The interrater reliability of all the outcome measures was at least moderate for all the measurements (Supplementary Table 1) .
Subject medical records after catheterization were reviewed to assess for postprocedural adverse events and other clinical outcomes. Subjects were considered at risk if an attempt was made to deploy (although not necessarily release) a device. Technical success was defined as successful deployment of a device without a residual shunt greater than 3 mm.
The major adverse events included device embolization, malposition followed by repeat intervention, procedureassociated cerebrovascular events, heart block persisting after the procedure, and death. The minor adverse events noted included arrhythmia, fever, hematoma (defined by follow-up notes from cardiologists or visits to other health care facilities), emesis, and pericardial effusion (not requiring intervention). Complications were subdivided between early (\30 days after the initial procedure) and late ([30 days after the initial procedure).
The early follow-up evaluation time of the included subjects was uniform, so event rates were described as risk per case. Late follow-up evaluation was not uniform, so the follow-up period was measured in terms of events per person-years of follow-up evaluation.
Clinical follow-up evaluation was calculated in two ways: first, as the time from ASD device deployment until the end of the study period, and second, as the time elapsed between the initial catheterization and the most recent documented clinical visit at our center. This provided bounds for measurement of time at risk. Echocardiographic follow-up time was determined as the time elapsed from catheterization to the most recent echocardiogram in the study period.
Statistical Analysis
Standard descriptive statistics were calculated. Continuous variables are expressed as mean ± standard deviation or median [range and interquartile range (IQR)] as appropriate. Categorical variables are described as proportions and counts.
The primary outcome of early adverse events was a composite of technical failure and/or early major adverse event, as defined earlier. Assessment of risk factors for a primary composite outcome was performed using logistic regression. Because this was an exploratory analysis, bivariable screening was used to identify risk factors, with potential risk factors included in the initial model if the p value was lower than 0.2 [24, 26] .
Before any testing, the decision was made to include deficient retro-aortic rim in the final model as the primary exposure. Backward selection was used to refine the model, with variables retained if the p value was lower than 0.05 or if their inclusion caused more than a 20 % change in the odds ratio (OR). Model fit was assessed post hoc with likelihood ratio testing for nested models or comparison of Akaike information criteria for both nested and non-nested models [26] .
Because the cohort size was fixed, no formal procedures were performed to calculate statistical power. No formal compensation for multiple comparisons was performed. For subjects with missing data, case elimination was used, and no attempt was made to replace missing data via imputation. The threshold for statistical significance was set at a p value lower than 0.05. All data analysis was performed using Stata SE v12 (Statacorp, College Station, TX, USA).
Results
Study Population
Between 1 January 1999 and 1 April 2012, 445 consecutive children and adults underwent cardiac catheterization for possible device closure of an ASD (Fig. 1) . The median age of these patients was 5.9 years (range, 0.8-80 years; IQR, 3.6-14.2 years), and their median weight was 21.7 kg (range, 5.4-132.5 kg; IQR, 15.2-15.7 kg) ( Table 1 ). Of the total study population, 15 % of the subjects had congenital heart disease in addition to their ASD, including 34 subjects (8 % of the study cohort) who had residual ASD after other cardiac operations and 32 subjects (7 % of the cohort) who had other anatomic cardiac disease without a previous operation. These counts do not include subjects with mild valvar pulmonic stenosis.
Of the original 445 subjects, 248 (56 %) had reviewable preprocedural echocardiograms (Fig. 1) . Of the 330 subjects with single ostium secundum ASD, 205 (62 %) had reviewable preprocedural TTE (Table 2) . Among the subjects with isolated secundum ASD, the median size of the secundum ASD on preprocedural TTE was 9.8 mm (range, 1-20.5 mm; IQR, 7.5-12.2 mm) in the subcostal frontal view and 9.5 mm (range, 3.9-26.3 mm; IQR, 7.7-12.1 mm) in the subcostal sagittal view ( Table 2) .
The median defect size with balloon sizing using the stop-flow technique was 14 mm (range, 5-38 mm; IQR, 12-19 mm). The median retro-aortic tissue rim size was 4.2 mm (range, 0-15.3 mm; IQR, 2.9-6.2 mm), with 60 % of the subjects having deficient retro-aortic rim. The prevalence of deficient retro-aortic rim was 61 % (116/ 190) among the subjects younger than 18 years, with images of the retro-aortic rim unavailable for six subjects, and 44 % (4/9) among the subjects older than 18 years, but this difference was not significant (p = 0.3).
Of the original 445 subjects, 3.6 % (n = 16) were deemed inappropriate for device closure and were referred for operative closure without attempted device placement. These were secondary to a combination of defect size, position, and rim size. None were due to insufficient retroaortic rim. Of the remaining 429 subjects who underwent attempted device closure, 96 % (n = 411) experienced technical success. A single ASO device was used in 61 % of the cases. A single HSO device was used in 24 % of the cases, and an NMT Starflex device was used in 9 % of the cases. The results for the subjects managed with multiple devices are summarized in Tables 3 and 4 . Among the subjects with single secundum ASD and deficient retroaortic rim (n = 116), device closure was accomplished with ASO in 67 % and with HSO in 33 % of the cases. No other devices were used for this subgroup.
For the subjects who underwent device occlusion with the ASO device, the median ratio of device diameter to balloon-sized defect diameter was 1.0 (range, 0.8-1.8; IQR, 1.0-1.1) (Tables 3, 4). Of subjects who had single secundum ASD occluded with ASO (n = 217), only one subject (0.5 %; 95 % CI, 0.01-2.5 %) had an ASO diameter-to-defect ratio greater than 1.5:1. For the subjects who had single secundum ASD occluded with the HSO device (n = 81), the median ratio of HSO diameter to defect size was 2.1 (range, 1.5-3.6; IQR, 1.7-3.1).
Follow-up Evaluation and Adverse Events
The 413 subjects who underwent device closure had a median total follow-up period of 5.8 years (range, 12 days to 12.6 years), for a total time at risk of 2,395 person-years. For 83 % of the subjects, a follow-up visit at our center was documented after discharge, with the most recent visit at a median time of 2.2 years (range, 2 days to 12.5 years), representing 1,079 person-years of time at risk. Follow-up echocardiograms could be reviewed for 330 subjects (80 %). The median echocardiographic follow-up period was 1.5 years (range, 1 day to 12.5 years), for a total of 845 person-years, with 267 subjects (65 %) undergoing echocardiograms after the first post-procedure day.
Of the 413 subjects with successful occlusion of their ASD, 319 (77 %) had clinical follow-up periods of at least 30 days. Adverse events within the first 30 days after follow-up evaluation are summarized in Table 5 . Major adverse events occurred for 1.1 % (95 % CI, 0.4-2.6 %) of the subjects, including three subjects (0.7 % of those undergoing device closure; 95 % CI, 0.1-2.0 %) in whom device embolization occurred and two subjects (0.4 % of those undergoing device closure; 95 % CI, 0.1-1.6 %) for whom device malposition resulted in reintervention.
All reinterventions were accomplished through repeat catheterization. Among these reinterventions, the only adverse event was new mild mitral regurgitation in a single patient after an HSO device embolized to the left ventricle and was retrieved with a snare catheter. One subject presented to the emergency department with fever and emesis 2 days after catheterization with a small pericardial effusion and was admitted for observation. The patient was eventually discharged without receiving medical therapy or any procedure to drain the effusion. Eight other subjects had trivial pericardial effusions (total n = 9, 5.7 % of subjects who underwent device closure with complete 30-day follow-up evaluation; 95 % CI, 3.2-9.4 %), none of which resulted in emergency room visits or hospitalization and all of which were self-resolved.
A total of 15 subjects (4.6 %; 95 % CI, 2.6-7.5 %) presented to an emergency room within 30 days after their procedure, with three resultant hospital admissions (0.9 %; 95 % CI, 0.2-2.7 %). In addition to the previously mentioned subject with a small pericardial effusion, seven subjects presented with headaches, three of whom were admitted for observation and symptom management. Two subjects with acute chest pain were seen in emergency departments, and one was admitted for observation. Evaluation demonstrated no evidence of a cardiac etiology. One IQR interquartile range; BMI body mass index; BSA body surface area; ASD atrial septal defect; CHD congenital heart disease; Qp:Qs ratio of pulmonary to systemic blood flow a Includes two or more races, deferred, or recorded as ''other'' b Trisomy 21 (n = 10), chromosomal abnormality not otherwise specified (n = 5), 22q11.2 deletion (n = 2), Noonan's syndrome (n = 2), Wolff-Hirschorn (n = 2), mosaic trisomy 13 (n = 1), unbalanced translocation of chromosome (n = 1), maple syrup urine disease (MSUD) (n = 1), CHAOS syndrome (n = 1), Perlman syndrome (n = 1), Turner syndrome (n = 1), 4q deletion (n = 1), Soto's syndrome (n = 1), and XXXXY (n = 1) c Pulmonary atresia intact ventricular septum (n = 12), tetralogy of Fallot (n = 10), transposition of the great arteries status after arterial switch operation (n = 6), tetralogy of Fallot pulmonary atresia (n = 2), hypertrophic cardiomyopathy s/p right ventricular outflow tract patch (n = 1), partial atrioventricular canal status after repair (n = 1), ASD repair at outside hospital (n = 1), interrupted aortic arch (n = 1), surgical valvotomy of pulmonary stenosis (n = 1) d ASD after balloon septostomy (n = 2), dehiscence of ASD patch in CCAVC (n = 1), and residual defect after suture repair at outside hospital (n = 1) e Includes 8 subjects with documented RV dilation and unretrievable Qp:Qs f One subject had Qp:Qs of 1.5 in addition to previous CVA g Prophylaxis before transvenous device (n = 1) and migraine headache (n = 1)
h Structural heart disease (15.1, 7.2 % of which are ASDs not left after operations), Ebsteins (n = 12), patent ductus arteriosis (PDA) (n = 10), restrictive ventricular septal defect (VSD) (n = 5), double aortic arch (n = 1), pulmonary AVM (n = 1), coronary to RPA fistula (n = 1), valvar and subvalvar pulmonic stenosis (n = 1), and PDA with VSD (n = 1). Previous arrhythmia (4 %) i Supraventricular tachycardia not otherwise specified (n = 6), atrioventricular nodal reentrant tachycardia (n = 4), long QT syndrome (n = 2), ectopic atrial tachycardia (n = 1), ventricular tachycardia (n = 1) j Congenital complete heart block (n = 3), first-degree AV conduction delay (n = 1) subject with a hematoma at the access site in the groin was seen and discharged from the emergency department without additional intervention. The remaining four visits were for chief complaints (gastroenteritis, viral respiratory infection, lymphadenitis, and chronic constipation) unrelated to the catheterization procedure. The risk factors for the composite outcome (technical failure to close the defect with a transcatheter device or major adverse event within 30 days after catheterization) were assessed using bivariable logistic regression, the results of which are summarized in Table 6 . Multivariable regression showed that the presence of deficient retroaortic rim did not increase the risk of the composite outcome and, if anything, appeared to have a nonsignificant association with reduced risk of combined adverse events (OR 0.28; 95 % CI, 0.08-1.01; p = 0.05). The ratio of pulmonary to systemic blood flow was associated with an increased risk of composite outcome (OR 2.57; 95 % CI, 1.2-5.4; p = 0.013).
After 30 days, no device embolization, malposition, device thrombus, new arrhythmia, stroke, or death were seen. No aortic erosions were observed, and no new peri- Qp:Qs ratio of systemic-to-pulmonary blood flow; IQR interquartile range; ASD atrial septal defect; ASO Amplatzer septal occluder device; LA left atrium; RA right atrium a No failures were recorded using STARflex or Amplatzer cribiform devices. On attempts with either ASO or Helex devices,the failure rate was 4.2 % (n = 16), with a success rate of 95.8 % (n = 368) b This number excludes cases in which multiple devices were deployed, as described later c These included the following: pulmonary artery balloon or stent angioplasty (n = 8), device occlusion of patent ductus arteriosus (n = 6), device occlusion of modified Blalock-Taussig shunt (n = 6), right ventricular outflow tract balloon angioplasty (n = 2) cardial effusions were noted. None of the trivial residual shunts underwent further intervention. New or increased aortic insufficiency was seen in seven subjects (2 %; 95 % CI, 0.9-4.5 %) between their precatheterization echocardiogram and their most recent postcatheterization echocardiogram. In one subject, new mild aortic insufficiency developed, with the remainder experiencing new trivial aortic insufficiency.
The association between deficient retro-aortic rim, device impingement, and aortic insufficiency was examined. For the 181 subjects with isolated secundum ASD and complete data, deficient retro-aortic rim was associated with an increased risk for impingement of the device on the aortic valve [relative risk (RR), 2.1; 95 % CI, 1.5-3.0; p \ 0.0001] ( Table 7) . For the subjects with deficient retro-aortic rim, deficient retro-aortic rim was significantly related to the two types of device impingement: impingement but no splaying (i.e., ''poking'') (RR 1.6) and impingement with splaying of the device (RR 2.2) (p = 0.002). Only a single example of poking with deformation of the valve was seen, so statistical inference was impossible. The incidence of new or increased aortic insufficiency was not associated with impingement of the ASD device (p = 0.66) nor with the specific type of impingement (p = 0.85) or deficient retro-aortic rim (p = 0.91). The low event rate was prohibitive for multivariate analysis.
Other risk factors for the development of aortic insufficiency were explored using additional univariate analyses. Device choice between ASO and HSO was not associated with risk of new aortic insufficiency (p = 0.96). Additionally, no association was seen between ratio of ASO size to septum (p = 1.0), HSO size to septum (p = 0.67), or ASO left atrial disc to septum (p = 0.92).
Discussion
This cohort study report summarizes the experience with device occlusion of ASD at a single center during a 12-year period. In this cohort, deficient retro-aortic rim was highly prevalent. The clinical significance of deficient retro-aortic rim is not clear. Deficient retro-aortic rim was associated with an increased risk for impingement of the device on the aorta but not with increased risk of early adverse outcome or development of aortic insufficiency. The subjects experienced no aortic erosions or late major adverse outcomes occurred. Thus, we cannot comment on the contribution of deficient retro-aortic rim to the risk of late adverse events or aortic erosion. We can state that it was not an independent risk factor for early adverse events or technical failure.
Device occlusion of ASD in the modern era has demonstrated excellent efficacy with procedural morbidity and mortality, comparing favorably with operative closure of ASD [8-10, 12, 14, 17-19, 22, 25, 27] . However, the occurrence of aortic erosion, a rare but potentially catastrophic complication, has inspired debate regarding the safety of device occlusion of ASD. A review of known aortic erosion cases implicated deficient retro-aortic rim (together with device-to-defect oversizing) as a potential risk factor for aortic erosion [4] . It is difficult to assess the contribution of deficient retro-aortic rim to risk, in part because its prevalence in patients referred for device closure has not been well described. To our knowledge, detailed echocardiographic assessment has not been included in studies of device occlusion. One study by Butera et al. [7] focusing on adult patients (median age, 29 years), measured the prevalence of deficient retro-aortic Cribiform device and ASO 2 (10)
ASO Amplatzer septal occluder device a All were two ASO except in one subject who received three ASO devices Table 5 Major and minor adverse events within 30 days after catheterization (n = 319) Event Risk (%) (95 % CI)
Major adverse event CI confidence interval a Major adverse events were defined as those requiring repeat catheterization or other intervention vs minor adverse events, which did not require repeat catheterization or other intervention rim as 24 %. Petit et al. [22] , in a series of young children (age \3 years), measured a prevalence of 59 %, identical to that measured in the current study (59 %; 95 % CI, 53-67 %). It should be highlighted that the current study included subjects from infancy to adulthood. No significant difference was demonstrated in the prevalence of deficient retro-aortic rim, which was highly prevalent among both children and adults, but the small number of adults in our series limited its statistical power. In this study, an attempt was made to determine whether deficient retro-aortic rim was a risk factor for adverse outcomes across longitudinal follow-up evaluations, and failing that, whether evidence existed to show that it increased the risk of precursors to aortic erosion. Deficient retro-aortic rim did not represent a risk factor for our composite outcome of technical failure or early major adverse events. Although not significant, the point estimate of its association with technical failure or major adverse outcome suggested that it was a protective factor. There is no mechanism that suggests why this would be true. Selection bias (e.g., excluding higher-risk patients with deficient retro-aortic rim) was not a likely cause because the study included periods before and after deficient retro-aortic rim was considered a risk factor for bad outcome.
The magnitude of left-to-right shunting (ratio of pulmonary to systemic blood flow) was an independent risk factor for our composite outcome. The magnitude of shunting was correlated with defect size (both on preprocedural and procedural echocardiograms; data not shown), and although the analysis was not designed to assess for shunting, it appeared to be a risk factor for increased risk of technical failure or major adverse outcome.
No aortic erosions or other late adverse outcomes occurred in our series, so the association between erosion and deficient retro-aortic rim cannot be assessed from our data. Initial reports proposed that the risk of aortic erosion was 1 in 1,000 cases [4] , with estimates of risk in the US of 0.07-0.11 % [11] . In this cohort, ASO devices were placed in 271 subjects (250 received single devices; 21 received either multiple ASO or ASO and another device to occlude multiple ASD), illustrating the limitations of even relatively large single-center studies to address this issue. However, using the available serial echocardiograms in our series, we attempted to assess potential risk factors for adverse outcomes, including device impingement on the aorta and new or progressive aortic insufficiency. Findings have not shown impingement to be a sufficient or necessary cause for aortic erosion, but insofar as it indicates contact between the device and the aorta, it was thought to be a potential risk factor. Development or progression of aortic insufficiency potentially indicates disruption of normal aortic valve function with the ASD device present. It has been noted after device occlusion of ASD in adults [23] but has not been associated with increased risk of any specific clinical outcomes (mortality or specific morbidity). The risk of new/progressive aortic insufficiency in our cohort was much lower than that reported in a single study of adults who underwent device occlusion, and the severity of resultant aortic insufficiency was qualitatively less.
From the current study, we can conclude that impingement occurs with and without deficient retro-aortic rim but more frequently with deficient retro-aortic rim. Aortic insufficiency developed in subjects without clear association with deficient retro-aortic rim or device impingement. Further study is necessary to determine whether impingement contributes to the risk of erosion and whether this is a potentially modifiable risk factor. It is clear that the causes of impingement and progressive insufficiency may be complicated and that single anatomic measurements may be insufficient to predict risk.
Study Limitations
No late adverse events occurred, so as noted, this study had limited utility to determine the association between deficient retro-aortic rim and the late outcomes described. In addition, the results were derived from a retrospective study at a single center and reflect the practice patterns at our institution. This limits our ability to comment on risk factors not observed commonly. For example, Amin et al. [4] identified device oversizing (ratio of ASO diameter to diameter of defect in balloon sizing [1.5:1) as a potential risk factor for aortic erosion. Only one subject in our cohort had an ASO-to-defect ratio greater than 1.5:1.
Another limitation of this study was missing data. Echocardiograms were reviewable for 56 % of the subjects. The subjects with echocardiograms that were not reviewable had procedures in an earlier period (preceding the adoption of digital recording and storage of studies at our institution). The prevalence of deficient retro-aortic rim likely did not change during the study period, and in an earlier era when deficient rim was not of clinical concern, its prevalence among treated subjects may have been even higher.
Follow-up evaluation also was not uniform. The majority of the subjects (77 %) received outpatient followup evaluation within our clinic system. The subjects without early clinical follow-up evaluation were not considered in the calculations of risk for early adverse events. To measure the time that the patients in the cohort were at risk for late adverse events, both a total follow-up time and a time from the procedure to the most recent clinic visit were included to provide conservative and liberal bounds. For other analyses, subjects with missing data were eliminated from analysis by case deletion.
Finally, the low incidence of adverse outcomes introduced the potential for type 2 error. Where possible, both p values and confidence intervals were included to reflect accurately the magnitude of uncertainty in risk. Further studies from multiple centers, especially using registry data, would be valuable to overcome these limitations and improve the generalizability of this study.
Conclusion
Deficient retro-aortic rim is highly prevalent among subjects referred for device occlusion of ASD and to the best of our knowledge does not represent a risk factor for technical failure, early adverse events, or the development of aortic insufficiency.
